Health and Healthcare

Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

250 Articles

Jon C. Ogg | Jan 14, 2014 at 8:15 AM EST

UBS Has Nine Biotech Buyout and Merger Candidates

The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility…

Jon C. Ogg | Jan 8, 2014 at 8:10 AM EST

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going…

Jon C. Ogg | Jan 6, 2014 at 9:00 AM EST

Ten Top Growth Stock Ideas for 2014 From Baird

Baird offers an eclectic and interesting list for investors. A top regional firm, it tends to dig a little deeper,…

Jon C. Ogg | Jan 6, 2014 at 8:45 AM EST

Top Analyst Upgrades and Stocks to Buy: AIG, Genworth, SolarCity and More

These are the top analyst upgrades, initiations and positive analyst research calls seen from Wall Street on Monday, January 6.

Trey Thoelcke | Dec 19, 2013 at 8:30 AM EST

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.

Jon C. Ogg | Nov 2, 2013 at 7:15 AM EDT

Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex

ThinkstockIdenix Pharmaceuticals Inc. (NASDAQ: IDIX) was the biggest gainer of all listed stocks on Friday with a rally of 40%.…

Lee Jackson | Sep 4, 2013 at 8:25 AM EDT

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013

ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive…

Jon C. Ogg | Aug 22, 2013 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: Microsoft, Target, Zynga and More

Jon OggNow that stocks have pulled back and interest rates have risen, investors are looking for more guidance on which…

Jon C. Ogg | Jul 12, 2013 at 8:15 AM EDT

Cowen’s Eight Biotech Stocks to Buy That Could Beat Earnings: Alexion, Ariad and More

ThinkstockBiotechnology stocks have had an extremely solid first half of the year. The analysts at Cowen Group point out that…

Jon C. Ogg | Jul 2, 2013 at 8:45 AM EDT

Which Biotech Stocks Are Buyout Targets After Onyx Pharmaceutical Rejects Amgen?

ThinkstockOn Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for…

Jon C. Ogg | Jun 13, 2013 at 8:15 AM EDT

Merrill Lynch Top Biotechnology Stocks to Buy for Big Gains

ThinkstockThe higher the market climbs, the harder it becomes for investors to find solid stock ideas to add or scale…

Jon C. Ogg | May 29, 2013 at 8:40 AM EDT

Top Analyst Downgrades and Stocks to Sell: Comerica, Maxim and SeaWorld

These are the top analyst downgrades, cautious research notes and stocks to sell from Wall Street for Wednesday, May 29,…

Jon C. Ogg | May 15, 2013 at 8:10 AM EDT

Deutsche Bank Firm on Biotech Stocks to Buy

ThinkstockBiotech has strongly outperformed the S&P 500 since January of 2011. The NASDAQ Biotechnology Index (NBI) is up 90%, and…

Paul Ausick | Apr 19, 2013 at 4:29 PM EDT

Market Close: Big Winners & Losers for April 19, 2013

thinkstockHere are today’s five biggest gaining stocks at closing: Vertex Pharmaceuticals Inc.(NASDAQ: VRTX) is up 61.9% at $85.60. Desarrolladora Homex…

Paul Ausick | Apr 19, 2013 at 4:06 PM EDT

24/7 Wall St. Closing Bell — April 19, 2013: After a Mixed Open, Markets Climb Slowly

U.S. equity markets opened mixed this morning as the DJIA was slammed by a number of weak earnings reports both…

1 … 10 11 12 13 14 … 17

Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

UBS Has Nine Biotech Buyout and Merger Candidates

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Ten Top Growth Stock Ideas for 2014 From Baird

Top Analyst Upgrades and Stocks to Buy: AIG, Genworth, SolarCity and More

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013

Top Analyst Upgrades and Downgrades: Microsoft, Target, Zynga and More

Cowen’s Eight Biotech Stocks to Buy That Could Beat Earnings: Alexion, Ariad and More

Which Biotech Stocks Are Buyout Targets After Onyx Pharmaceutical Rejects Amgen?

Merrill Lynch Top Biotechnology Stocks to Buy for Big Gains

Top Analyst Downgrades and Stocks to Sell: Comerica, Maxim and SeaWorld

Deutsche Bank Firm on Biotech Stocks to Buy

Market Close: Big Winners & Losers for April 19, 2013

24/7 Wall St. Closing Bell — April 19, 2013: After a Mixed Open, Markets Climb Slowly

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

UBS Has Nine Biotech Buyout and Merger Candidates

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Ten Top Growth Stock Ideas for 2014 From Baird

Top Analyst Upgrades and Stocks to Buy: AIG, Genworth, SolarCity and More

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013

Top Analyst Upgrades and Downgrades: Microsoft, Target, Zynga and More

Cowen’s Eight Biotech Stocks to Buy That Could Beat Earnings: Alexion, Ariad and More

Which Biotech Stocks Are Buyout Targets After Onyx Pharmaceutical Rejects Amgen?

Merrill Lynch Top Biotechnology Stocks to Buy for Big Gains

Top Analyst Downgrades and Stocks to Sell: Comerica, Maxim and SeaWorld

Deutsche Bank Firm on Biotech Stocks to Buy

Market Close: Big Winners & Losers for April 19, 2013

24/7 Wall St. Closing Bell — April 19, 2013: After a Mixed Open, Markets Climb Slowly

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s